Carried by SCOPP/SFCO
Clinician referent : Jean-Yves BLAY
Biologist referent : Anne-Paule GIMENEZ ROQUEPLO
Patients with rare cancers that have relapsed or are incurable, treated within one of the INCa-accredited networks or by other networks. Any new patient with a rare* solid tumour, regardless of the existence of a specialised INCa rare cancer centre, regardless of the stage of the disease, with a life expectancy of more than 3 months.
*annual incidence of fewer than 6 cases per 100,000 inhabitants
| INCa networks | Types of rare cancers |
| NETSARC+ | Sarcomas and aggressive connective tissue tumours |
| RENOCLIP-LOC | Rare cancers of the central nervous system |
| TMRO-TMRG | Malignant tumours of the ovary and other gynaecological tumours |
| CARADERM | Rare skin cancers |
| RYTHMIC | Thymic epithelial tumours |
| RENAPE | Rare tumours of the peritoneum |
| GFELC | Cutaneous lymphomas |
| CELAC | Lymphomas associated with coeliac disease |
| PREDIR | Von Hippel-Lindau disease and other hereditary predispositions to kidney cancer |
| K-VIROGREF | Viral-induced cancers following transplantation |
| REFCOR | Rare head and neck cancers |
| TTG | Gestational trophoblastic tumours |
| MELACHONAT | Ocular melanomas |
| CANCERVIH | Cancers in people living with HIV |
| ENDOCAN-COMETE | Rare adrenal tumours and cancers |
| ENDOCAN RENATEN | Neuroendocrine tumours and carcinomas |
| ENDOCAN-TUTHYREF | Refractory thyroid tumours |
| Outside INCa networks | Rare cancers |